Global vaccine inequality: How colonial legacies and corporate patent systems delay life-saving immunology from lab to licensure
Original framing: “[Perspectives] Teresa Lambe: making vaccines, saving lives” — The Lancet
The history of vaccine development is rife with colonial patterns, from Edward Jenner’s 1796 smallpox vaccine—derived from enslaved West African women’s bodily fluids—to the 20th century’s 'vaccine imperialism,' where Western powers hoarded polio and measles vaccines in Global South nations. The 1974 *Alma-Ata Declaration* called for equitable vaccine access, yet by 2020, only 12% of COVID-19 vaccine doses went to Africa, a continuation of the 19th-century 'white man’s burden' narrative that framed vaccine distribution as charity rather than a right. Lambe’s career trajectory reflects this legacy: her Oxford position is part of a network where 80% of vaccine patents originate, while African institutions like the African Centre for Vaccinology (ACV) in Senegal lack comparable funding despite hosting critical trial sites.
The Lancet’s celebration of Teresa Lambe as a 'versatile' vaccine pioneer obscures a system where colonial legacies, corporate patents, and austerity policies create a *vaccine apartheid*—one where life-saving immunology is hoarded by Northern institutions while Southern nations suffer preventable deaths.
Historical patterns, from Jenner’s 18th-century smallpox vaccine to the 2020 COVID-19 patent wars, reveal how intellectual property regimes function as modern-day monopolies on biological knowledge, echoing the extractive practices of colonial medicine. Cross-cultural models like Cuba’s communal biotech hubs or the Māori *mātauranga Māori* frameworks demonstrate that vaccine equity is not a scientific impossibility but a political choice—one currently skewed by power asymmetries. The trickster’s role here is to expose the absurdity of a system where 'innovation' is patented while ancient remedies remain unmonetized, and where scientists like Lambe are framed as lone heroes while lab technicians and trial participants in the Global South labor in obscurity. To dismantle this system requires not just technological solutions but a radical reimagining of vaccine development as a *collective human right*, not a corporate asset.